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In Brief
Glomerular podocytes form the third and
most outer layer of the kidney filtration
barrier responsible for restricting the
passage of proteins into the urine.
Brinkkoetter et al. show that podocyte
metabolism primarily relies on anaerobic
glycolysis and the fermentation of
glucose to lactate.
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https://doi.org/10.1016/j.celrep.2019.04.012SUMMARY
The cellular responses induced by mitochondrial
dysfunction remain elusive. Intrigued by the lack
of almost any glomerular phenotype in patients
with profound renal ischemia, we comprehensively
investigated the primary sources of energy of
glomerular podocytes. Combining functional mea-
surements of oxygen consumption rates, glomerular
metabolite analysis, and determination of mitochon-
drial density of podocytes in vivo, we demonstrate
that anaerobic glycolysis and fermentation of
glucose to lactate represent the key energy source
of podocytes. Under physiological conditions, we
could detect neither a developmental nor late-onset
pathological phenotype in podocytes with impaired
mitochondrial biogenesis machinery, defective
mitochondrial fusion-fission apparatus, or reduced
mtDNA stability and transcription caused by podo-
cyte-specific deletion of Pgc-1a, Drp1, or Tfam,
respectively. Anaerobic glycolysis represents the
predominant metabolic pathway of podocytes.
These findings offer a strategy to therapeutically
interfere with the enhanced podocyte metabolism
in various progressive kidney diseases, such as dia-
betic nephropathy or focal segmental glomerulo-
sclerosis (FSGS).Ce
This is an open access article under the CC BY-NINTRODUCTION
Mitochondria are key organelles for cellular bioenergetics and
constantly undergo dynamic remodeling processes, including
fusion and fission to adjust to the cellular demand for energy.
Mitochondrial dysfunction, impaired energy homeostasis, as
well as an increased production of reactive oxygen species are
associated to a variety of human disorders, including aging-
associated diseases (Bratic and Larsson, 2013; Nunnari and
Suomalainen, 2012) as well as kidney diseases (reviewed in
O’Toole, 2014). The contribution of mitochondrial dysfunction
to disease onset or progression—either directly due to genetic
mutations or indirectly as a consequence of an altered cellular
homeostasis—remains unclear, especially in complex multi-
causal disorders, such as diabetic nephropathy, the leading
cause of end-stage renal disease (ESRD) in western countries.
Therefore, understanding the functional role of mitochondria in
the two essential compartments of the kidney, i.e., glomerulus
and tubular system, is a crucial first step.
Mitochondria are the primary cellular source of ATP and
essential for all eukaryotic cells (Detmer and Chan, 2007). They
are highly dynamic structures that constantly divide and fuse
to build an intracellular network that assures the distribution
within the cell and is required to execute their pleiotropic activ-
ities, including among others aerobic ATP production, governing
metabolic pathways, as well as apoptosis, participation in RNA
and DNA production, and the biosynthesis of heme, certain
amino acids, and lipids (Ising et al., 2015; Osman et al., 2011;
Schmidt et al., 2010). In addition, the inner mitochondrialll Reports 27, 1551–1566, April 30, 2019 ª 2019 The Authors. 1551
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membrane potential participates in the uptake of cytosolic Ca2+
and potentially serves as buffer for locally increased intracellular
Ca2+ levels (von Kleist-Retzow et al., 2007). To this end, mito-
chondria maintained their ability for self-replication to face the
metabolic energy demands of the cell. Adaptive mechanisms
of the mitochondrial network operating energy metabolism
and mitochondrial self-renewal are mitochondrial biogenesis
and mitochondrial dynamics regulated by key molecules,
including mitochondrial transcription factor A (TFAM), peroxi-
some proliferator-activated receptor gamma coactivator
1-alpha (PGC-1a), and dynamin-related protein 1 (DRP-1).
Primary mitochondriopathies mainly affect the CNS and skel-
etal muscle. In most cases, the renal involvement is limited to
tubular dysfunction, comprising Fanconi or Bartter-like syn-
dromes or renal tubular acidosis (reviewed in Che et al., 2014),
reflecting the high ATP demand derived from mitochondrial
OXPHOS necessary for electrolyte-transporting processes
within the tubular apparatus. Only sporadically, mitochondriopa-
thies are also linked to glomerular disease, in particular focal
segmental glomerulosclerosis (FSGS) and steroid-resistant
nephrotic syndrome (reviewed in O’Toole, 2014). Moreover,
another highly relevant clinical condition, i.e., acute kidney injury
(AKI), emphasizes a different role of mitochondria in the two kid-
ney compartments. AKI due to ischemia and reperfusion injury
causes severe tubular dysfunction and, eventually, tubular ne-
crosis and necroptosis (reviewed in Kers et al., 2016), whereas
the glomerular compartment remains functionally and morpho-
logically intact. These findings cannot be simply explained by
general differences in the cellular energy demand. As tubular
function can be characterized as a highly energy-consuming
process, so does the maintenance of the structural integrity of
the glomerular filter.
The majority of kidney diseases evolve from the glomerulus,
the renal filtration unit. The glomerular filter is composed of three
anatomic layers: the fenestrated endothelial cell layer; the
glomerular basement membrane (GBM); and the slit diaphragm
between adjacent podocyte foot processes. Podocytes are peri-
cyte-like epithelial cells that cover the outer aspect of the
glomerular capillaries (reviewed in Brinkkoetter et al., 2013).
The cells have to apply static forces to cope with the pulsating
glomerular capillaries to maintain the glomerular filtration barrier.
These include adaptive processes comprising actin-based
cytoskeletal remodeling and hypertrophy to adjust for filtration
demands. The critical function of these processes has been
demonstrated in various podocyte-specific knockout ap-
proaches targeting hypertrophy and actin remodeling (Go¨del
et al., 2011; Schell et al., 2013; Zschiedrich et al., 2017), all lead-
ing to a uniform pathological sequel involving foot processFigure 1. Podocytes Display Low Mitochondrial Density
(A) Image obtained by transmission electronmicroscopy (TEM) displaying a glome
and a proximal tubular cell, respectively. Mitochondria are marked by arrowhead
fication of mitochondrial density and distribution of mitochondria in podocytes
presented as mean ± SD).
(B) Principal-component analysis (PCA) of metabolite content of glomeruli and th
(C) Heatmap of metabolites detected in glomeruli and in the tubular compartmen
(D) Metabolite composition of glomerular and tubular samples based on supercl
(E) Abundance of intermediates of tricarboxylic acid (TCA) cycle in glomeruli andeffacement and detachment, and proteinuria is the most sensi-
tive clinical parameter reflecting podocyte damage (de Jong
and Curhan, 2006; Pinto-Sietsma et al., 2000).
In order to sustain the complex cellularmorphology of interdig-
itating foot processes, podocytes rely on a constant energy sup-
ply and reservoir. It is so far not yet clear what kind of energy
resources and pathways are mainly exploited under physiolog-
ical conditions (Abe et al., 2010; M€uller-Deile and Schiffer,
2014). Moreover, there are conflicting results in glomerular dis-
ease concerning the role of mitochondria (Doleris et al., 2000;
Hotta et al., 2001; Imasawa and Rossignol, 2013; Kurogouchi
et al., 1998; Yamagata et al., 2002), suggesting an unmet need
to delineate the bioenergetic framework required to maintain
the glomerular filter under physiological conditions and charac-
terize the role of mitochondria in this unique functional compart-
ment. Here, we applied an unbiased metabolomic approach to
determine the podocytes’ energy supply chain with special
emphasis on the contribution of mitochondria. Therefore, we
employed conditional in vivo targeting strategies specifically in
podocytes to interfere with mitochondrial biogenesis by
depleting PPARGC1A (later referred to as Pgc-1a), to inhibit
mitochondrial fission by depleting DNM1L (later referred to as
Drp1), and to diminish mtDNA copy number and transcription
by deleting Tfam.
RESULTS
Podocytes Display Low Mitochondrial Density
First, we performed transmission electron microscopy (TEM) to
study the mitochondrial abundance and localization within
glomerular podocytes. To this end, we analyzed 70 TEM pictures
from 8 wild-type mice (Figure 1A). Podocytes showed a signifi-
cantly lower mitochondrial density per cell area as compared
to renal tubular cells (0.7 ± 0.7 versus 4.1 ± 1.6; p % 0.001).
Moreover, in podocytes, mitochondria were primarily found
within the cytoplasm (71%) and primary processes (29%) but
rarely seen within secondary processes. 3D-reconstructed
glomeruli stained for the mitochondrial enzyme SOD2 (superox-
ide dismutase 2) and the glycolytic enzyme PKM2 (pyruvate ki-
nase M2) confirmed the perinuclear localization of mitochondria
(Figure S1A), whereas PKM2was found ubiquitously, suggesting
podocyte processes as a large putative compartment of anaer-
obic glycolysis (Figures S1B–S1D). Principal-component anal-
ysis (PCA) of metabolite content of glomeruli and the tubular
compartment (obtained from 4 mice each) revealed a distinct
metabolite pattern (Figures 1B and 1C), with high levels of amino
acids (86%) and low levels of carbohydrates (12%) and
lipids (1.4%) in glomeruli, although in the tubular compartment,rulus with neighboring tubular cells. Boxed areas show details from a podocyte
s. The depicted image is stitched from a 333 array of single images. Quanti-
(based on the analysis of 70 pictures obtained from 8 mice; ***p % 0.001;
e tubular compartment (obtained from 4 mice each).
t (obtained from 4 mice each).
asses of metabolites.
the tubular compartment.
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carbohydrates were most abundant (carbohydrates 62%, amino
acids 21%, and lipids 14%; Figure 1D). These observations of
fundamental metabolic differences were also reflected by low
levels of intermediates of the tricarboxylic acid cycle (TCA) found
in glomeruli compared to the tubular compartment (7% versus
93%; Figure 1E).
Glycolysis and oxidative phosphorylation (OXPHOS) are the
two major cellular pathways to produce energy. Most cells
may switch between these pathways in order to cope with
changing energy demands. Glycolysis reflects the conversion
of glucose into pyruvate and, subsequently, into lactate in the
cytoplasm (anaerobic glycolysis) or into CO2 and H2O within
mitochondria (aerobic glycolysis). In addition, mitochondrial
energy may also be derived from oxidation of fatty acids and
glutamine. The podocytes’ mitochondrial dependency on and
flexibility for each of these energy sources can be determined
by measuring the decline in oxygen consumption rate (OCR)
upon addition of specific inhibitors (dependency % = [baseline
OCR  target inhibitor OCR/baseline OCR  all inhibitors
OCR] 3 100; capacity % = (1  [baseline OCR  other 2 inhibi-
tors OCR]/[baseline OCR  all inhibitors OCR]) 3 100). To gain
further insights in the podocytes’ energy sources under physio-
logical conditions, we isolated primary podocytes fromwild-type
reporter mice (Figure 2A). First, we analyzed the mitochondrial
contribution to the energy supply chain. Administration of
etomoxir, an inhibitor of long fatty acid oxidation, resulted in a
significant decrease in OCR, and inhibition of glutamine
(by bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide
[BPTES]) or pyruvate (by UK5099) oxidation resulted in marginal
reductions of OCR only (Figures 2B–2D). These findings revealed
that podocytes primarily utilize fatty acid oxidation and oxidation
of glutamine or pyruvate is of minor importance (Figures 2C–2F).
Next, we aimed to differentiate the podocytes’ dependency on
the anaerobic glycolysis and the activity of the respiratory chain.
To this end, we measured the OCR of primary podocytes after
administration of 2-deoxyglucose (2-DG), a glycolysis inhibitor
competitively inhibiting the production of glucose-6-phosphate
or vehicle followed by specific inhibitors (oligomycin, carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone [FCCP], and rote-
none/antimycin A) of the respiratory chain (Figure 2G). TheFigure 2. Primary Podocytes Rely on Glycolysis
(A) Primary podocyte culture was obtained by crossing hNPHS2Cre mice with
fluorescence-activated cell sorting (FACS) is shown.
(B) Dependency and capacity of fatty acid oxidation obtained after etomoxir
respectively (mean ± SD). Final concentrations: etomoxir: 100 mM; BPTES: 30 mM
(C) Dependency and capacity of glutamine oxidation obtained after BPTES an
(mean ± SD). Final concentrations: etomoxir: 100 mM; BPTES: 30 mM; UK5099: 3
(D) Dependency and capacity of pyruvate oxidation obtained after UK5099 an
(mean ± SD). Final concentrations: etomoxir: 100 mM; BPTES: 30 mM; UK5099: 3
(E) Statistics displaying substrate dependency of primary podocytes (data out o
(F) Statistics displaying substrate capacity of primary podocytes (data out of 3 e
(G) Oxygen consumption rate (OCR) of primary podocytes after injection of 2-d
indicated (mean ± SD). Final concentration: 2-DG: 50 mM; oligomycin: 1 mM; FC
(H) Extracellular acidification rate (ECAR) of primary podocytes obtained after i
(mean ± SD). Final concentration: 2-DG: 50 mM; oligomycin: 1 mM; rotenone: 0.5
(I) ECAR of primary podocytes after oxamate or vehicle injection (mean ± SD). F
(J) Statistics displaying ECAR after vehicle or oxamate injection (***p% 0.001; m
(K) Statistics showing intracellular ATP content after 24-h treatment with 2-DG,
concentration: 2-DG: 50 mM; oxamate: 45 mM; etomoxir: 100 mM; oligomycin: 1administration of 2-DG did not affect the OCR neither at baseline
nor after addition of the OXPHOS inhibitors. We also measured
the extracellular acidification rate (ECAR) to determine the
release of protons into the supernatant as a result of the activity
of the glycolysis pathway (Figure 2H). Podocytes showed a rapid
glucose-induced increase in glycolytic activity with a maximal
glycolytic capacity of 3.1 ± 0.5 mpH/min/1,000 cells after inhibi-
tion of the mitochondrial ATP production by addition of oligomy-
cin. These findings were further substantiated by assessing the
oxamate-sensitive ECAR rate (Figures 2I and 2J), confirming
the observation that podocytes harbor a strong glycolytic
activity. Last, we assessed the contribution of the distinct ATP-
generating pathways to the overall ATP production in podocytes
(Figure 2K). Although inhibition of the anaerobic glycolysis by
administration of 2-DG or oxamate resulted in a significant
decrease in the cellular ATP content, inhibition of O2-dependent
pathways, including fatty acid oxidation, was of minor relevance.
Taken together, low mitochondrial abundance, decreased levels
of TCA intermediates, as well as a strong dependency on the
anaerobic glycolysis support the hypothesis that podocytes do
not primarily rely on mitochondrial energy resources under
physiological conditions. To further substantiate this hypothesis,
we explored phenotypes in three independent mouse models
to interfere with mitochondrial function within podocytes
specifically.
Podocytes Do Not Rely on Functional Mitochondrial
Fission Machinery
First, we evaluated the structural and functional consequences
of a targeted deletion of Drp1 and the inability to undergo mito-
chondrial fission in podocytes. We monitored knockout and
respective wild-type animals for a period of 12 months. Within
this time period, we did not observe significant differences in
body weight gain or any increase in urinary albumin excretion,
excluding podocyte dysfunction in Drp1 podocyte knockout an-
imals (Figure 3). Histological evaluation revealed no obvious
morphological alterations up to 12 months of age (Figure 3H).
Using TEM, we visualized the mitochondrial morphology in po-
docytes of 1-, 5-, and 7-month-old Drp1flox/flox*hNPHS2Cre
knockout and Drp1flox/flox control mice. Although mitochondriaa Tomato/EGFP reporter strain. Schematic of glomerular culture followed by
and BPTESm UK5099 injection or BPTES, UK5099 followed by etomoxir,
; UK5099: 30 mM.
d etomoxir, UK5099 or etomoxir, UK5099 followed by BPTES, respectively
0 mM.
d etomoxir, BPTES and etomoxir, BPTES followed by UK5099, respectively
0 mM.
f 3 experiments; *p% 0.05; **p% 0.01; mean ± SD).
xperiments; *p% 0.05; **p% 0.01; mean ± SD).
eoxyglucose or vehicle followed by the inhibitors of the respiratory chain as
CP: 0.5 mM; rotenone: 0.5 mM; antimycin: 0.5 mM.
njection of glucose or vehicle followed by oligomycin and 2-DG as indicated
mM; antimycin: 0.5 mM.
inal concentration: oxamate: 45 mM.
ean ± SD).
oxamate, etomoxir, or oligomycin (*p % 0.05; ** p % 0.01; mean ± SD). Final
mM.
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in podocytes of 1-month-old knockout mice seemed to form a
more distinctive tubular network, no other major abnormalities
were detected (Figures 4A and 4B). At months 5 and 7, mito-
chondria of Drp1 knockout mice appeared slightly swollen,
probably reflecting the consequences of deficient mitochondrial
division and accumulation of oxidative stress. However, even at
these later time points, no signs of podocyte foot process efface-
ment were detectable in Drp1 knockout mice (Figures 4C–4F).
To further delineate the function of Drp1 on podocyte meta-
bolism, in vivo and in vitro mtDNA levels were quantified in
isolated glomeruli obtained from 24-week-old mice with
podocyte-specific deletion of Drp1 and respective controls as
a surrogate parameter of mitochondrial density. mtDNA was
significantly reduced in mice lacking DRP1, as highlighted by
reduced Atp6 and Cox1 abundance compared to 18 s (Fig-
ure S2A). Functionally, gas chromatography-mass spectrometry
(GC-MS) profiling from kidney cortex of respectivemice revealed
only minor differences on overall metabolite content and similar
levels of lactate (Figure S2B). To further elucidate the potential
impact of Drp1 depletion on podocyte metabolism, small inter-
fering RNA (siRNA)-based knockdown approaches were per-
formed with subsequent metabolic profiling. Using this
approach, cellular DRP1 content significantly decreased (Fig-
ure S2C); however, mitochondrial function and glycolysis as
well as glycolytic capacity remained unaffected (Figures S2D–
S2G). Maximal respiratory capacity as assessed after FCCP
exposure was even increased compared to siScrambled con-
trols, suggesting a role of DRP1 inmitochondrial stress response
(Figure S2E). Assessment of the main mitochondrial fuel
confirmed fatty acids a key source of podocyte OXPHOS.
Knockdown of Drp1, however, did not affect mitochondrial fuel
preference (Figures S2H–S2O). In summary, Drp1 deletion
impacted the expression of certain mitochondria-encoded
genes; however, further functional effects were not detectable.
Mitochondrial Biogenesis Is Dispensable for Podocyte
Function
Next, we interfered with mitochondrial biogenesis and deleted
Pgc-1a in podocytes specifically. We monitored Pgc-1a
knockout and respective wild-type animals for a period of
22 months. Again, we did not observe any significant differences
neither in body weight nor in urinary albumin excretion (Figure 5).
Histological evaluation revealed no obvious morphological alter-Figure 3. Loss of DRP1 Does Not Affect Glomerular Function and Mor
(A) Schematic illustrating targeted gene deletion approach of Drp1 in podocytes
(B) Breeding strategy to generate a podocyte-based reporter strain. After isolatio
were verified using the following primers: D1 (50-CACTGAGAGCTCTATATGTAG
TAAAGTGGACAAGAGGTCC-30). PCR products were detected at 315 bp and 53
(C) Western blot analysis confirmed reduced DRP1 levels in glomeruli of conditio
(D) Densitometric quantification of DRP1 protein levels demonstrated a significan
(E) Immunofluorescence stainings visualized absence of DRP1 in knockout podo
with NEPHRIN staining.
(F) 12-month follow-up period revealed no differences in body weight between w
point were analyzed; mean ± SD).
(G) Measurement of ACR (albumin-to-creatinine ratio) revealed no differences du
point were analyzed; mean ± SD).
(H) Periodic acid Schiff (PAS)-stained kidney sections obtained from 1-month
showed normal glomerular structure.ations nor did we detect structural mitochondrial defects by TEM
(Figures 5E and 5F). Ultrastructure of podocyte foot processes
remained intact (Figure 5F). Functionally, Pgc-1a deletion
reduced the mtDNA content in mouse glomeruli with regard to
Atp6 levels, suggesting reduced mitochondrial biogenesis (Fig-
ure S3A). However, GC-MS profiling of kidney cortex of mice
with podocyte-specific deletion of Pgc-1a and respective con-
trols revealed only minor changes in overall metabolite content.
Accordingly, lactate levels did not differ between the genotypes
(Figure S3B). Knockdown of Pgc-1a in human podocytes signif-
icantly reduced mitochondrial function and increased glycolysis
and glycolytic capacity (Figures S3C–S3G), thereby demon-
strating the impact of Pgc-1a on mitochondrial biogenesis in po-
docytes and anaerobic glycolysis as a ‘‘back up’’ pathway to
cover podocyte’s energy demands. Depletion of PGC-1a did
not impact mitochondrial substrate preference, as seen bymain-
tained high levels fatty acid dependency and capacity (Figures
S3H–S3O).
Loss of Mitochondrial Transcription and Lack of the
OXPHOS Machinery Does Not Result in Podocyte
Disease
Furthermore, we studied podocyte-specific Tfam knockout mice
in order to provide additional in vivo evidence and to test the
hypothesis that podocytes do not rely on the mitochondrial
OXPHOS machinery. We followed knockout and wild-type ani-
mals for a period of 12 months and assessed renal function
and proteinuria. As shown for Drp1 and Pgc-1a podocyte-spe-
cific knockout mice, again, we did not observe any significant
differences neither in body weight nor in urinary albumin excre-
tion (Figure 6). Histological evaluation revealed no obvious
morphological alterations (Figure 6H). Additional TEM studies
in 20- and 55-week-old animals revealed a regular slit diaphragm
structure (Figure S4A) and no major structural abnormalities in
mitochondrial morphology or number (Figures S4B and S4C).
However, Tfam depletion significantly reduced mtDNA content
in ex vivo isolated glomeruli (Figure S5A) and showed the stron-
gest impact on overall metabolite composition as seen in the
principal-component analysis (Figure S5B) compared to the
other knockout models. In particular, lactate levels significantly
increased if TFAM is lacking. Transient knockdown of Tfam in hu-
man podocytes (as demonstrated in Figure S5C) significantly
reduced mitochondrial respiration and respiratory capacityphology
using the Cre-loxP system.
n of GFP+ podocytes via FACS, DNA was prepared and respective genotypes
GC-30); D3 (50-ACCAAAGTAAGGAATAGCTGTTG-30); and D5 (50-GAGTACC
9 bp.
nal Drp1flox/flox*hNPHS2Cre mice.
t reduction in glomeruli derived from KO animals (n = 3; *p% 0.05; mean ± SD).
cytes. Dotted lines indicate the respective podocyte compartment, as marked
ild-type and Drp1 knockout animals (at least 3 animals per genotype and time
ring the 12-month follow-up period (at least 3 animals per genotype and time
-old and 12-month-old Drp1flox/flox*hNPHS2Cre mice and littermate controls
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Figure 4. Mitochondria Are Elongated in Drp1-Deficient Podocytes
Representative TEM pictures displaying mitochondrial shape and density in podocytes. Sections were obtained from mouse kidneys at the age of 1 month,
5 months, and 7 months, respectively.(Figures S5D and S5E). Glycolysis and glycolytic capacity signif-
icantly increased (Figures S5F and S5G). As seen in Drp1 and
Pgc-1a knockdown experiments, fatty acids remain the main
fuel for podocyte OXPHOS in vitro (Figures S5H–S5O).
Because knockdown of Tfam by using siRNA did not allow for
complete abrogation of the protein, we aimed to further validate
our findings by isolating primary podocytes after additional mat-
ings of Tfam podocyte knockout mice with a fluorescent reporter
mouse (Figure 7A). Surprisingly, we did not observe any clear
morphologic effect on the mitochondrial network (Figure 7B).
However, as a result of the decrease in TFAM, we observed a dif-
ferential regulation of proteins of the respiratory chain. Protein
expression of mitochondrial-encoded genes, such asmtNdufb8,
mtCO1, and ATP5A, were strongly decreased, reflecting an
abrogated mitochondrial transcription and a strong reduction
of complex I, IV, and V of the respiratory chain. The level of ubiq-
uinol-cytochrome C reductase (UQCR) of complex III was only
slightly reduced. By contrast, we did observe a strong reduction
in the succinate dehydrogenase (ubiquinone) iron-sulfur subunit
(SDHB) of complex II in the absence of TFAM, which is primarily1558 Cell Reports 27, 1551–1566, April 30, 2019nuclear encoded (Figure 7C). OCR of Tfam knockout podocytes
was strongly reduced, indicating severe abrogation of OXPHOS
as intended (Figures 7D and 7E). Severe mitochondrial dysfunc-
tion was associated with strongly reduced reactive oxygen spe-
cies (ROS) production as observed in Tfam knockout podocytes
compared to wild-type (WT) and heterozygous Tfam deletion
(Figure 7F). Surprisingly, anaerobic glycolysis and glycolytic ca-
pacity decreased as well in vitro (Figures 7G and 7H), however,
still allowing for maintained podocyte ATP supply, as indicated
by podocyte integrity in vivo. In summary, compared to the other
knockout models in this study, deletion of Tfam showed the
strongest impact on mitochondrial function and podocyte meta-
bolism in vivo and in vitro. Neither Drp1 nor Pgc-1a or Tfam dele-
tion was able to induce phenotypic abnormalities in podocytes
in vivo. Accordingly, GC-MS profiling revealed only slight and
distinct metabolic changes in ex vivo isolated kidney cortex of
thesemice (Figures S6A and S6B), suggesting a functionally fully
compensated metabolic state due to increased anaerobic
glycolysis in these models if mitochondria become genetically
targeted.
(legend on next page)
Cell Reports 27, 1551–1566, April 30, 2019 1559
DISCUSSION
Mitochondria are semi-autonomous organelles, the ‘‘cell’s po-
wer plants,’’ that produce the most of its ATP supply via the
OXPHOS. Beyond energy supply, they are involved in crucial
pathways for homeostasis, phagocytosis, and apoptosis. Mito-
chondria are also recognized as an important signaling platform
that utilizes molecules like ADP and ATP, Ca2+, respiratory chain
metabolites, ROS, or the unfolded protein response to regulate
cross-communication with other organelles and the nucleus (re-
viewed in Raimundo, 2014). Preservation and fitness of this
crosstalk, under physiological or stress conditions, is necessary
for normal cell function and homeostasis and alterations often
result in pathological phenotypes. However, the regulatory
mechanisms of this vital communication between the cell
compartments in states of health and disease remain unclear.
Mitochondrial genome regulation as well as the organelles distri-
bution into the cell—specified by balanced fission and fusion—
must be in accordance to tissue-dependent cellular needs.
Respiratory activity of each tissue type determines the energetic
threshold under which mitochondrial impairment leads to a dis-
ease phenotype. Although, so far, mitochondrial diseases were
assigned to OXPHOS impairment, during the last years there
are accumulating data supporting that impairment of mitochon-
dria signaling can lead to disease independently of the energy
production levels (Raimundo et al., 2012).
It is the matter of a long-standing debate to what extent the
resident cells of the glomerulus, and in particular the podo-
cytes, contribute actively to the filtering process. Glomeruli
are thought to filter the plasma continuously, but filtration rates
vary strongly dependent on physiological regulation, nephron
type, and metabolic activity (Singer, 2001). There is, however,
a general consensus that podocytes are essential for the
buildup of the glomerular filtration barrier as they orchestrate
glomerular endothelial cell functions through secreted vascular
endothelial growth factor (VEGF; reviewed in Bartlett et al.,
2016) and maintain the structural and functional integrity of
the glomerular basement membrane (reviewed in Miner,
2012). Moreover, the fact that GBM and slit diaphragm compo-
nent synthesis occurs in podocytes reveals their crucial role in
maintaining the kidney filtration barrier, as well as their involve-
ment in glomerular disease development. Podocytes represent
the outer layer of the vascular filter counterbalancing mechanic
forces as the result of a pulsatile blood flow. Hence, it is not sur-
prising that podocytes harbor an actin-based cytoskeleton,Figure 5. Podocyte-Specific Pgc-1a Knockout Mice Are Viable and Do
(A) Schematic illustrating targeted gene deletion approach of Pgc-1a in podocyt
(B) After isolation of podocytes via antibody-based labeling followed by FACS, D
primers: Pgc-1a WT: forward 50-ACCTGTCTTTGCCTATGATTC-30, reverse
GATTTATGAC-30, reverse 50-CCAACTGTCTATAATTCCAGTTC-30.
(C) In a 22-month follow-up period, no differences in bodyweight were detected be
and time point were analyzed; mean ± SD).
(D) Measurement of ACR revealed no differences during the 22-month follow
mean ± SD).
(E) PAS-stained kidney sections from 3-month-old and 22-month-old Pgc-1a
structure.
(F) TEM images obtained from 22-month-old Pgc-1aflox/flox*hNPHS2Cre and li
mitochondrial shape (representative pictures).
1560 Cell Reports 27, 1551–1566, April 30, 2019including a contractile machinery allowing rapid shape remod-
eling and podocyte movement (Peti-Peterdi and Sipos, 2010).
Podocytes fine-structure and function maintenance implies
metabolic activity, but so far their detailed metabolic profile re-
mains obscure (reviewed in Imasawa and Rossignol, 2013). In
2010, Abe and colleagues provided first experimental evidence
for a critical role of mitochondria and, in particular, a high de-
pendency of podocytes on mitochondrial energy delivery using
an immortalized podocyte cell line (Abe et al., 2010). Inhibition
of glycolysis or oxidative phosphorylation each reduced ATP
levels and were thought to explain the susceptibility of podo-
cytes to oxidative stress as observed in patients with diabetic
nephropathy. On the contrary, Ozawa et al. (2015) suggested
that both glycolytic andOXPHOS pathways contribute to podo-
cyte energy supplements, depending on the intracellular sub-
localization of mitochondria and on the cell differentiation
status. Imassawa et al. (2017) recorded that high-glucose con-
ditions forced differentiating human podocyte cell lines to
switch from OXPHOS to glycolysis, resulting in lactic acidosis.
Here, we provide comprehensive metabolomics data from
freshly isolated glomeruli and primary podocytes as well as
the results from three independent mouse models highlighting
the podocytes’ independence from mitochondrial energy sour-
ces. In contrast, we observed, both in vitro and in vivo, a strong
dependency on cytosolic degradation of glucose to lactate.
Neither impaired mitochondrial biogenesis nor defective fission
machinery nor mitochondrial transcription resulted in podocyte
dysfunction. These experimental findings challenge our view on
the mitochondrial contribution to podocyte function and the
metabolic status of podocytes in general. Primarily, podocytes
do not rely on mitochondrial energy sources under physiolog-
ical conditions but rather metabolize glucose to lactate instead
to meet their energy needs—very similar to Warburg’s hypoth-
esis for cancer cells and many in vitro cell culture systems. Po-
docytes are terminally differentiated quiescent cells. There is
accumulating evidence that quiescence is accompanied with
strong metabolic changes in order to ensure the maintenance
of the cell’s proper function and survival. This metabolic switch
from mitochondrial respiration to glycolysis or vice versa is not
uniform but rather depends on the cell type and cell environ-
mental context (reviewed in Valcourt et al., 2012). For instance,
hematopoietic cells dependence on glycolysis for energy pro-
duction is related to their localization in a hypoxic niche in the
bone marrow (Simsek et al., 2010). Nephron progenitors’ local-
ization in hypoxic niche also appears to be strongly related toNot Display a Glomerular Phenotype
es using the Cre-loxP system.
NA was prepared and respective genotypes were verified using the following
CCAGTTTCTTCATTGGTGTG; Pgc-1a KO forward 50-TCCAGTAGGCAGA
tweenwild-type andPgc-1a knockout animals (at least 3 animals per genotype
-up period (at least 3 animals per genotype and time point were analyzed;
flox/flox*hNPHS2Cre mice and littermate controls showed normal glomerular
ttermate controls show normal foot process formation and no difference in
(legend on next page)
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glomerulogenesis through HIF-1a and HIF-2a possible interac-
tion with VEGF (reviewed in Hemker et al., 2016).
We hypothesize that podocytes counteract cellular acidifica-
tion due to the accumulation of lactate by secretion into the pri-
mary urine surrounding the podocytes’ cell bodies. The most
convincing evidence to support our hypothesis and the indepen-
dence of podocytes from mitochondrial ATP production comes
from clinical observations. Acute kidney injury (AKI) is defined
as progressive loss of renal function within hours and often oc-
curs due to a sudden decrease in renal blood flow, leading to kid-
ney ischemia. Patients suffering from AKI usually present with
elevated blood urea nitrogen and creatinine levels and a reduc-
tion in urine output. Rarely, increased levels of albuminuria are
observed, excluding a significant contribution of the glomerular
filtration barrier to the course of disease.
Based on our experimental data, we now speculate that not
the loss of mitochondrial OXPHOS is detrimental for podocyte
function and, eventually, survival but rather a change in podocyte
metabolism. The impact of Drp1, Pgc-1a, or Tfam depletion on
mitochondrial function and podocyte metabolism was only mi-
nor, with the strongest changes in overall metabolite content
toward increased anaerobic glycolysis being observed in the
TFAM-deficient podocytes. Overall, these observations suggest
a fully compensated metabolic state due to increased anaerobic
glycolysis in these models if mitochondria become genetically
targeted.
In the light of recent data, we speculate that mitochondria are
critical regulators of metabolic signaling events in podocytes,
with mTOR being the ultimate cellular effector kinase (Fantus
et al., 2016; Grahammer et al., 2014). Mice with a genetic abla-
tion of prohibitin-2, a scaffold protein in the inner mitochondrial
membrane that does not affect the OXPHOS machinery, dis-
played a severe glomerular disease phenotype and premature
death after 4 or 5 weeks, which could be ameliorated by inter-
fering with the insulin-signaling cascade and its downstream
mediator mTOR (Ising et al., 2015). Similarly, a transgenic mouse
model with genetic activation of mTOR resulted in increased
metabolic signaling and the onset of FSGS (Zschiedrich et al.,
2017). Notably, the knockout of mTORC1 by induced deletion
of both Raptor alleles was also found to be detrimental and led
to an accelerated progression of FSGS. In contrast, lowering
mTORC1 activity by genetic depletion of one Raptor alleleFigure 6. Podocyte-Specific Tfam Knockout Mice Do Not Develop Glo
(A) Schematic illustrating targeted gene deletion approach of Tfam in podocytes
(B) After isolation of glomeruli, DNAwas prepared and respective genotypes were
Tfam reverse 1 50-GTAACAGCAGACAACTTGTG-30; Tfam reverse 2 50-CTCTGAA
(C) Immunofluorescence staining for TFAM in kidney sections obtained from 3-m
(D) 12-month follow-up period revealed no differences in body weight between wi
3 animals per genotype and time point were analyzed; mean ± SD).
(E) Urinary protein excretion was absent during a 12-month follow-up perio
respectively, as indicated by representative Coomassie brilliant blue staining.
(F) Serum creatinine levels in 6-month-old Tfamflox/flox, Tfamflox/+*hNPHS2Cre
mean ± SD).
(G) Serum urea levels in 6-month-old Tfamflox/flox, Tfamflox/+*hNPHS2Cremice and
(H) PAS-stained kidney sections obtained from 55-week-old Tfamflox/flox, Tfamflox
(I) Glomerulosclerosis assessment in kidney sections obtained from 55-week-old
(1991). Adriamycin-induced nephropathy in WT mice (ICR-CD1 background sac
100 glomeruli were assessed per mouse; mean ± SD).
1562 Cell Reports 27, 1551–1566, April 30, 2019ameliorated the progression of glomerulosclerosis in various dis-
ease models (Go¨del et al., 2011; Zschiedrich et al., 2017). Taken
together, these findings lead to the hypothesis that mTOR serves
as key regulator of podocyte metabolism without affecting the
preferences for the used metabolic pathways. We did not
observe a compensatory upregulation of the mitochondrial
OXPHOS machinery in the absence of neither Pgc-1a nor
Drp1.We can only speculate on the observed decrease in glycol-
ysis in Tfam knockout (KO) podocytes. This effect could reflect
the reduced CO2 emission by the OXPHOS machinery—also it
contributes only very little to the overall ATP content. However,
it could also be secondary to the cell isolation protocol, which
may result in cellular stress—a condition during which the mito-
chondrial OXPHOS machinery is required to ascertain cellular
function and survival, even though we did not observe an
increased rate of cell death in the Tfam knockout cells as
compared to the control cells. The metabolic framework charac-
terized in this study primarily reflects podocyte metabolism
under physiological, non-stressed conditions. It provides an
experimental basis to extend our understanding on the mito-
chondrial contribution to podocyte diseases. The independence
of mitochondrial ATP production under physiological conditions
not only represents a functional reserve in post-mitotic podo-
cytes but furthermore serves as intracellular source for increased
amounts of reactive oxygen species and thereby, ultimately,
increased cellular damage and podocyte loss as reported for
diabetic nephropathy as a result of hyperglycemia (Ayanga
et al., 2016; Chung et al., 2003; Eid et al., 2009; Lee et al.,
2003). Along these lines, Qi and colleagues reported in 2017
(Qi et al., 2017) a differential upregulation of enzymes in the
glycolytic, sorbitol, methylglyoxal, and mitochondrial pathways
to be protective in the setting of diabetic kidney disease. In
particular, activation of PKM2 was shown to be protective
against diabetic nephropathy (DN) by increasing glucose meta-
bolic flux, inhibiting the production of toxic glucose metabolites
and inducing mitochondrial biogenesis to restore mitochondrial
function. Hence, a differential and well-orchestrated regulation
of multiple signal pathways is required to overcome the delete-
rious effects of increased mitochondrial ROS, which is distinct
from the basal independence of podocytes on the mitochondrial
ATP, content. Interfering with the production or scavenging of
ROS might represent suitable therapeutic strategies to treatmerular Disease
using the Cre-loxP system.
verified using following primers: Tfam forward 50-CTGCCTTCCTAGCCCGG-30;
GCACATGGTCAAT-30.
onth-old Tfamflox/flox*hNPHS2Cre mice and respective controls.
ld-type, Tfamflox/+*hNPHS2Cremice and Tfamflox/flox*hNPHS2Cremice (at least
d in Tfamflox/flox, Tfamflox/+*hNPHS2Cre mice and Tfamflox/flox*hNPHS2Cre,
mice and Tfamflox/flox*hNPHS2Cre mice, respectively (n = 4 each genotype;
Tfamflox/flox*hNPHS2Cremice, respectively (n = 4 each genotype; mean ± SD).
/+*hNPHS2Cre mice and Tfamflox/flox*hNPHS2Cre mice, respectively.
Tfamflox/flox and Tfamflox/flox*hNPHS2Cre mice, as proposed by el Nahas et al.
rificed 50 days after induction) served as positive control (n = 3 each group;
(legend on next page)
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patients with DN (Bhatti and Usman, 2015). Activation of the
Nrf2/Keap1 pathway by small molecules may serve as one
example currently undergoing extensive clinical testing (de
Haan, 2011). There is additional, mostly circumstantial data
from in vitro and in vivo models, suggesting a contribution of
OXPHOS pathways to the development of podocyte disease.
In particular, increased activity of PGC-1a and, as a result,
increased mitochondrial biogenesis has been reported to
contribute to the development of collapsing glomerulopathy (Li
et al., 2017), and it appeared to be protective in a model of aldo-
sterone-induced podocyte injury (Zhao et al., 2016). Hyperglyce-
mia itself has been reported to activate podocyte metabolism by
inducing DRP1-mediated mitochondrial fission through ROCK1
(Wang et al., 2012). As it relates to TFAM and the role of mtDNA
stability and mtDNA transcription, very little is known about its
importance for kidney cells although global deletion of Tfam
was embryonically lethal (Larsson et al., 1998). Kidneys from het-
erozygous Tfam+/ mice present with mtDNA depletion that is
not followed by OXPHOS deficiency (Larsson et al., 1998) More-
over, TFAM overexpression in mice leads to mtDNA copy num-
ber increase in all tissues—including kidney—without affecting
mtDNA expression and OXPHOS function (Ekstrand et al.,
2004). Conditional disruption of Tfam expression in heart and
skeletal muscle cells resulted in a severe phenotype and death
of the animals after 2–4 weeks of age (Wang et al., 1999),
although loss of TFAM in epidermal progenitor/stem cells
(EPSCs) had no effect on epidermal development and skin
barrier function (Baris et al., 2011), very similar to the lack of
any disease phenotype as reported for podocytes in this study.
Differential regulation of the different complexes of the OXPHOS
machinery in the absence of TFAM, including the nuclear-en-
coded genes of complex II as observed in this study and also
by Vernochet et al. (2012) in brown adipose tissue, may
contribute to the tissue-specific consequences of a targeted
Tfam deletion, ranging from the absence of any phenotype to
embryonic lethality.
In conclusion, this study provides insights into podocytemeta-
bolism as podocytes primarily rely on anaerobic glycolysis and
only to aminor extent on b-oxidation of lipids. Overall, mitochon-
drial oxidative phosphorylation has only very limited impact on
the overall podocyte ATP synthesis. As such, anaerobic glycol-
ysis and the fermentation of glucose to lactate is the predomi-
nant metabolic pathway of podocytes and therefore represents
a key target for therapeutic interventions in glomerular disease
with enhanced metabolism, such as diabetic nephropathy.Figure 7. Metabolic Profiling of Tfam-Deficient Podocytes Revealed D
(A) Schematic illustrating breeding strategy to generate primary podocytes lackin
(B) Immunofluorescence image obtained from primary podocytes deficient for T
chondrial marker TOMM20 (red).
(C) Western blot analysis for key components of the respiratory chain revealed low
(D) OCR from Tfam-deficient podocytes and controls at baseline and after subse
Final concentration: oligomycin: 1 mM; FCCP: 0.5 mM; rotenone: 0.5 mM; antimyc
(E) Statistics of key parameters of respiratory function in Tfam-deficient podocyt
(F) Quantitative CM-H2DCFDA fluorescence obtained from primary podocytes
oxidative stress (**p% 0.01; ***p% 0.001; mean ± SD).
(G) Extracellular acidification rate of Tfam-deficient podocytes and respective
oligomycin and 2-DG (mean ± SD). Final concentration: glucose: 10 mM; oligom
(H) Statistics of key parameters of glycolytic activity obtained from Tfam-deficien
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-podocin Sigma P0372
anti-TOMM20 Santa Cruz sc-11415
anti-TFAM Santa Cruz sc-23588
anti-DRP1 BD Transduction 611112
anti-NEPHRIN Progen GP-N2
anti-SYNAPTOPODIN Synapotic Systems 163 004
anti-PKM2 Cell Signaling D78A4
anti-SOD2 Acris Antibodies APO3023PU-S
anti-alpha TUBULIN Sigma T6199
anti-PGC-1a Merck Milipore 4C1.3
OXPHOS Rodent WB Antibody Cocktail Abcam Ab110413
anti-ATP Abcam AB113849
Bacterial and Virus Strains
Chemicals, Peptides, and Recombinant Proteins
CM-H2DCFDA Invitrogen C6827
oligomycin Sigma 75351
FCCP Sigma C2920
antimycin A Sigma A8674
rotenone Abcam Ab14315
etomoxir Sigma E1905
BPTES Sigma SML0601
UK5099 Sigma PZ0160
2-DG Sigma D6134
oxamate Sigma O2751
Critical Commercial Assays
Seahorse XFp Mito Fluel Flex Test Agilent Technologies N/A
Mito Stress Test Agilent Technologies N/A
Seahorse XF Glycolysis Stress Test Kit Agilent Technologies N/A
Experimental Models: Cell Lines
Immortalized human podocytes Saleem et al., 2002 N/A
Experimental Models: Organisms/Strains
B6.129S4(FVB)-Ppargc1atm1Brsp/J Lin et al., 2004 N/A
B6.Drp1flox/flox/J Wakabayashi et al., 2009 N/A
B6.Tfamflox/flox/N Larsson et al., 1998 N/A
B6.hNPHS2Cre Moeller et al., 2003 N/A
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J Jackson Laboratory N/A
Oligonucleotides
Tfam forward 50-CTGCCTTCCTAGCCCGG-30 Larsson et al., 1998 N/A
Tfam reverse 1 50-GTAACAGCAGACAACTTGTG-30 Larsson et al., 1998 N/A
Tfam reverse 2 50-CTCTGAAGCACATGGTCAAT-30 Larsson et al., 1998 N/A
Pgc-1a WT: frwd 50-ACCTGTCTTTGCCTATGATTC Lin et al., 2004 N/A
Pgc-1a WT: reverse 50- CCAGTTTCTTCATTGGTGTG 30 Lin et al., 2004 N/A
Pgc-1a KO forward: 50-TCCAGTA GGCAGAGATTTATGAC-30 Lin et al., 2004 N/A
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Pgc-1a KO reverse: 50-CCAACTGTCTATAATTCCAGTTC-3 Lin et al., 2004 N/A
Drp1: D1 50-CACTGAGAGCTCTATATGTAGGC-30 Wakabayashi et al., 2009 N/A
D3 50-ACCAAAGTAAGGAAT AGCTGTTG-30 Wakabayashi et al., 2009 N/A
D5 50-GAGTACCTAAAGTGGACAAGAGGTCC-30 Wakabayashi et al., 2009 N/A
cox1 Thermo Fisher Scientific Mm04225243_g1
Atp6 Thermo Fisher Scientific Mm03649417_g1
18S Thermo Fisher Scientific Hs99999901_s1
siRNA Drp1, Pgc1alpha and Tfam On Target Smart Pool, Dharmacon N/A
Software and Algorithms
Imaris software v7.6 Bitplane N/A
LabImage ID software Kapelan Bio-Imaging N/A
Seahorse XFp software version 2.2.0 Seahorse Bioscience N/A
GraphPad Prism Version 6 GraphPad Software N/A
MetaboAnalyst Xia and Wishart, 2016 N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tobias B.
Huber (t.huber@uke.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Mice: B6.129S4(FVB)-Ppargc1atm1Brsp/J were a generous gift from B. Spiegelman (Lin et al., 2004). Drp1flox/flox mice (Wakabayashi
et al., 2009) on C57BL/6J background were a generous gift fromH. Sesaki (Johns Hopkins University School of Medicine, Baltimore).
Tfamflox/flox mice (Larsson et al., 1998) on C57BL/6N background were a generous gift from N.G. Larsson (Max Planck Institute for
Biology of Aging, Cologne/Germany). All mice were backcrossed to pure C57BL/6J or 6N background, respectively. To obtain a po-
docyte-specific knockout ofDrp1, Tfam and Pgc-1a, respectively, mice harboring the respective floxed allele were further crossed to
hNPHS2Cremice provided by L. Holzman (Renal, Electrolyte and Hypertension Division, University of Pennsylvania School of Med-
icine, Philadelphia, PA, USA) to generate a podocyte specific knockout. Only male mice were phenotypically analyzed (cohort size:
Drp1: n = 10; Pgc-1a: n = 6, Tfam: n = 8; control cohorts (WT) include 10, 6 and 8 mice, respectively). Male hNPHS2Cre negative
littermates served as controls. All animal experiments were conducted according to the guidelines of the Committee on Research
Animal Care and the German and Swiss law for the welfare of animals. All experiments were approved by local authorities (Regier-
ungspraesidium Freiburg (G11/38, G14/45), Kantonales Veterina¨ramt of the Kanton Basel and the LANUV NRW (State Agency for
Nature, Environment and Consumer Protection North Rhine-Westphalia), respectively. Mice had free access to chow and water
and a 12-hour day/night cycle. Breeding and genotyping was done according to standard procedures. To isolate primary podocytes
Tfamflox/flox*hNPHS2Cre+ were crossed to Tomato/eGFP reporter mice. Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J mice
were purchased from Jackson Laboratory (Bar Harbor, ME). Tfamflox/flox; Tomato/eGFP*hNPHS2Cre+ and WT;Tomato/
eGFP*hNPHS2Cre+ were chosen for primary cell isolation.
Primary Cell Culture
Isolation of primary podocytes was performed as recently described (Schell et al., 2013). In brief glomeruli from 2 week old
Tfamflox/flox;Tomato/eGFP;hNPHS2Cre+ andWT;Tomato/eGFP;hNPHS2Cre+ mice, respectively, were isolated by sieving. After cul-
ture of 5 days FACS procedure was performed to isolate the GFP-positive population of primary podocytes. For all ex vivo experi-
ments podocytes were kept in 5.5mM D-glucose reflecting normoglycemic conditions.
METHOD DETAILS
Urine and serum analysis
Urinary albumin was analyzed with Coomassie gel stains and measured using a fluorimetric albumin test kit (Progen, PR2005). Uri-
nary creatinine was measured using enzymatic colorimetric creatinine kit (Labor+Technik, LT-CR0053) as described in the manufac-
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Histology and electron microscopy
Kidneys were fixed in 4% paraformaldehyde and embedded in paraffin and further processed for PAS and HE staining. For quanti-
tative assessment of glomerular lesions as previously described by El Nahas (el Nahas et al., 1991) 2 mmPAS stained kidney slides of
at least 3 animals were analyzed for focal (1 point) or total sclerosis (2 points). The sum was divided by the number of counted
glomeruli. This was done in a blinded fashion and repeated by a second renal pathology experienced scientist.
For transmission electronmicroscopy, tissue blocks were washed after post fixation in 0.1MPB, and sections (thickness: 50 mm) of
the kidney were cut by using vibratome. After incubation in 1%OsO4, the sections were stained with uranyl acetate, dehydrated and
flat embedded in epoxy resin (Durcupan ACM, Fluka, Sigma-Aldrich, Gillingham, UK). 40 nm ultrathin sections were cut and analyzed
using an 80kV Zeiss Leo transmission electron microscope.
Ex vivo podocyte isolation and DNA isolation and PCR
To confirm the podocyte-specific knock out of Tfam, Pgc-1a andDrp1, respectively, podocytes were ex vivo isolated after Dynabead
perfusion and several digestion steps. Finally, podocytes were captured by anti-podocin antibody (P0372, Sigma) coupled to Alexa
Fluor 488 (Z25302, Thermo Scientific) (Pgc-1a) or isolated due to their GFP-signal (Tfamflox/flox;Tomato/eGFP;hNPHS2Cre+ and
Drp1flox/flox;Tomato/eGFP;hNPHS2Cre+ mice). DNA was isolated using DNeasy kit (QIAGEN, 69504) following manufacturer‘s in-
structions. PRC was performed using following primers: Tfam forward 50-CTGCCTTCCTAGCCCGG-30, Tfam reverse 1 50-GTAA
CAGCAGACAACTTGTG-30, Tfam reverse 2 50-CTCTGAAGCACATGGTCAAT-30. Pgc-1a alpha primer: Pgc-1a WT: frwd 50-ACCT
GTCTTTGCCTATGATTC, reverse 50- CCAGTTTCTTCATTGGTGTG 30; Pgc-1a KO forward: 50-TCCAGTA
GGCAGAGATTTATGAC-30, reverse: 50-CCAACTGTCTATAATTCCAGTTC-30.
Drp1: D1 (50-CACTGAGAGCTCTATATGTAGGC-30), D3 (50-ACCAAAGTAAGGAAT
AGCTGTTG-30) and D5 (50-GAGTACCTAAAGTGGACAAGAGGTCC-30).
Staining of podocytes and ROS detection
Primary podocytes obtained from Tfamflox/flox;Tomato/eGFP;hNPHS-Cre+ and WT; Tomato/eGFP;hNPHS2Cre+ mice were seeded
on collagen coated coverslips. 24h later cells were fixed with paraformaldehyde (4% in phosphate buffered saline (PBS)) and stained
with rabbit anti TOMM20 (Santa Cruz, sc-11415).
For ROS detection primary podocytes were seeded in a 96 well plate with clear flat bottom and black sides the day before the
experiment (25 000 cells/well). After washing podocytes were incubated in 5 mM working solution of CM-H2DCFDA (Invitrogen,
C6827) at 37C in the dark. CM-H2DCFDA was replaced by PBS and excitation/emission was measured (485/535nm) in a plate
reader (Tecan Infinite).
Immunofluorescence staining
Tfamflox/flox*hNPHS2Cre and Drp1flox/flox*hNPHS2Cre and respective controls were perfused with phosphate buffered saline (PBS)
via cardiac perfusion. For TFAM staining mice kidneys were fixed in 4% formaldehyde, embedded in paraffin and cut in 4 mm sec-
tions. Samples were deparaffinized in xylene and rehydrated in ethanol gradient (100% - 95% - 70%). The slides were washed with
TBST (Tris-buffered-saline with 0.025%Tween 20) and boiled in Tris-EDTA pH 9.0 for 10min to obtain antigen retrieval. After washing
with milliQ water and TBST samples were blocked with 5% BSA and 5% normal donkey serum in TBST for 1 hour at room temper-
ature. Incubation with primary antibodies overnight at 4C was followed by secondary antibodies for 60 min at room temperature.
Following antibodies were used: anti mtTFA (A-17) (Santa Cruz, sc-23588), anti PODOCIN (Sigma, P0372). Imaging was performed
with a Leica DMI 6000 B invertedmicroscope - HCX PL APO 63x/1.40 oil immersion objective. All images were further processedwith
the CorelDRAW(R) Graphics Suite X6.
For DRP1 staining, kidneys were snap-frozen in cryogenic Tissue-Tek O.C.T. compound (ElectronMicroscopy Sciences) and 4 mm
cryosections were generated with a Leica Kryostat (Leica, Wetzlar, Germany). Sections were fixed with PFA 4%, followed by treat-
ment with NH4CL (50 mM) and blocking with 5% BSA in PBS. Subsequently the sections were incubated with following primary an-
tibodies for 60minutes: anti-DRP1 (BD Transduction) and anti-NEPHRIN (guinea pig, 1:300, Progen) After several rinses, appropriate
fluorophore-conjugated Alexa secondary antibodies (Invitrogen) in a final dilution of 1:500 were applied for 30 minutes. Images were
taken using a Zeiss fluorescence microscope.
For localization studies of glycolysis (assessed for PKM2 distribution) and mitochondrial distribution (assessed for SOD) indirect
immunofluorescence was performed following the protocol described above. Podocytes were identified using synaptopodin (Syn-
aptic Systems; 163 004), glycolytic enzyme abundance was assessed via PKM2 (Cell Signaling Technology D78A4) and mitochon-
drial distribution was visualized via SOD2 expression (Acris Antibodies; APO3023PU-S). Image acquisition was performed using a
scanning confocal microscope (LSM800, Zeiss) with airy scan function, which allowed image post processing. 3D reconstructions,
distributions and volumetric calculations (i.e., maximal distance to podocyte nuclei) were performed based on 6 stacks per group by
using Imaris software v7.6 (Bitplane).
Cell and glomerular lysis and western blot procedure
Glomeruli were isolated by Dynabead perfusion. Cells were harvested by trypsinization and lysis was performed using RIPA buffer.
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SDS-PAGE. Afterward, gels were transferred to a polyvinyl difluoride membrane (iBlot Gel Transfer Stacks, Life Technologies,
IB401001) by dry blotting technique (iBlot 2 Dry Blotting System, Life technologies). Membranes were blocked in 5% PBS-BSA
Following antibodies were used for western blot: anti b-ACTIN (Sigma, A9357), anti-alpha TUBULIN (Sigma, T6199), anti DRP-1
(Cell Signaling Technology, D6C7), anti TFAM (Abcam, ab131607), anti PGC-1a (Merck Milipore, 4C1.3), total OXPHOS Rodent
WB Antibody Cocktail (Abcam, ab110413). Densitometry was performed using LabImage ID software (Kapelan Bio-Imaging).
qPCR for mitochondrial and nuclear DNA targets
DNA was extracted out of ex vivo isolated glomeruli (Dynabead perfusion for high purity, 4 mice per genotype at the age of 24 weeks)
using the QIAGEN DNeasy Blood & Tissue kit according to the manufacturer’s instructions and total concentrations were measured
with the Thermo Fisher NanoDrop spectralphotometre. DNA was diluted to 2,5ng/ml and the individual dilution factors were noted
down. mtDNA copy numbers were assessed by conducting qPCR, in which 18S was used for measurement of genomic DNA and
served as loading control and Rnr2 and cox1 were used for measuring mitochondrial genes (Thermo Fisher Scientific, cox1:
Mm04225243_g1; Atp6: Mm03649417_g1; 18S: Hs99999901_s1). Measurements were compared to five standard dilutions, ranging
from undiluted to the highest dilution factor used when diluting the DNA isolated out of podocytes. Four technical replicates were
measured per sample.
Seahorse XFp mitochondrial analysis and ATP measurement
Optimization of cell density for primary podocytes as well as optimization of the working concentration titers for each individual in-
hibitor was conducted prior to the Seahorse XFp experiments according to the manufacturer‘s instructions (Agilent Technologies).
Cells were seeded at a density of 20 000 cells/well. The Seahorse XFpMito Fluel Flex Test, Mito Stress Test and assessment of glyco-
lytic activity was performed following the manufacturer‘s instruction. Specifically, podocytes on XFp microplates were rinsed. XF
assay buffer was added. Afterward the plate was equilibrated for 1 h at 37C in a non-CO2 incubator. All medium and solutions of
mitochondrial complex inhibitors were adjusted to pH 7.4 on the day of assay. Following four baseline measurements of OCR
and ECAR, inhibitors of the respiratory chain were sequentially injected into each well. Three OCR and ECAR readings were taken
after addition of each inhibitor and before automated injection of the subsequent inhibitor. Mitochondrial complex inhibitors, in order
of injection, included oligomycin (1 mM) to inhibit complex V, FCCP (0.5 mM) to uncouple the proton gradient, antimycin A (1.0 mM,
inhibitor of complex III), and rotenone (1.0 mM, complex I inhibitor). For Mito Fuel assessment etomoxir, BPTES, UK5099 were
used with final concentration of 100 mM (etomoxir) and 30 mM (BPTES, UK5099). OCR and ECAR were automatically calculated
by Seahorse XFp software version 2.2.0 (Seahorse Bioscience, Billerica, MA, USA). After each experiment podocytes were fixed
with paraformaldehyde and nuclei were stained with DAPI. Olympus ScanR Screening Station for high-throughput microscopy
detection (Olympus, Tokyo, Japan) was used for assessment of cell number to normalize XFp analysis data.
Knock-down experiments for Drp1, Pgc-1a and Tfam, respectively, were performed in immortalized human podocytes (kindly
provided by Moin Saleem (Bristol, UK)) (Saleem et al., 2002). Podocytes were seeded in RPMI 1640 supplemented with 10%
FCS, Insulin/Transferrin/Selenite, Penicillin/Streptomycin (all fromRoche Diagnostics, Mannheim, Germany), Pyruvate, 100xMinimal
Essential Medium and HEPES Buffer (all Life technologies, Darmstadt, Germany). When cells had grown to 60% confluence differ-
entiation was induced at 37.0C for 10–14 days. Cultured human podocytes were fully differentiated before any experiment.
Knock-down experiments for Drp1, Pgc-1a and Tfam, respectively, were performed by using predesigned pooled siRNA (four tar-
geting one gene, On target SMART pool, Dharmacon). Transfection was performed by using electroporation (Amaxa nucleofector
technology, Lonza) according to manufacturer’s instructions. Efficiency of the knockdown was confirmed 48 hours after transfection
using western blot. The Seahorse XFpMito Fluel Flex Test, Mito Stress Test and assessment of glycolytic activity was performed 48h
after transfection.
For ATP measurement primary podocytes were treated with 2-DG (50 mM), oxamate (45 mM), etomoxir (100 mM) and oligomycin
(1mM) and ATP measurement was performed using luminescent ATP detection (Abcam 113849) following the manufacturer‘s
instructions.
GC/MS based untargeted metabolomics screen
Glomeruli were ex vivo harvested using Dynabead perfusion. Tubular compartment was isolated by microdissection. To assess the
impact of Drp1, Pgc-1a and Tfam deletion, respectively, on metabolite profiles, kidney cortex obtained from 24-week-old mice from
each genotype and respective controls were analyzed (n = 4 each). All tissue preparation was performed on ice in less than 30 s.
Metabolites were extracted in 90% methanol and 10% water at 20C containing 1 mg/ml ribitol and 1 mg/ml phenylglucose as in-
ternal standards. Tissue lysis was performed by using a Precellys 24 homogenizer with screw cap vials prefilled with 300 mg glass
beads (diameter 600 mm) as follows: two times three cycles of 30 s homogenization and 30 s break at 20C. Further sample pro-
cessing and metabolic profiling was conducted as described by Willmann et al. (2015). In summary, after centrifugation, metabolite
containing supernatant was dried overnight and the pellet was derivatized by methoxyamination and silylation. Untargeted GC/MS
profiling was performed with a 30 m HP5-MS column coupled to an electron impact mass spectrometer. Features were deconvo-
luted, aligned and annotated according to mass spectral similarity and retention index of three different libraries. The principal
component analysis (PCA) and heatmap were generated by MetaboAnalyst (Xia and Wishart, 2016).e4 Cell Reports 27, 1551–1566.e1–e5, April 30, 2019
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
Results of all experiments are presented as mean ± SD. To test for statistical significance of observed effects two-tailed t test was
used calculated with GraphPad Prism (Version 6, GraphPad Software, La Jolla, California, USA). p value% 0.05 represented statis-
tically significant differences.Cell Reports 27, 1551–1566.e1–e5, April 30, 2019 e5
